TIDMNSCI
NetScientific PLC
09 February 2017
NetScientific plc
("NetScientific" or the "Company" or the "Group")
Vortex Biosciences' Chief Scientific Officer, Elodie Sollier,
Selected as Finalist for 2017 SLAS Innovation Award
London, UK - 9 February 2017 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation Group, is delighted to report that the Chief
Scientific Officer of its portfolio company, Vortex Biosciences,
Elodie Sollier, has been selected as a finalist for a 2017 SLAS
Innovation Award.
Elodie, who is one of nine finalists, gave a presentation to the
judges on Monday 6 February: "Vortex Technology for fast and
label-free isolation of circulating tumour cells from blood
samples" where she discussed a breakthrough by Vortex in the
isolation of circulating tumour cells from blood samples. Her
presentation will be considered by the judges in determining the
winner of the award.
The annual SLAS Innovation Award recognizes extraordinary
achievement in innovative life sciences discovery and technology.
All those selected to deliver podium presentations at the annual
SLAS conference are eligible to be considered for this award, which
comes with a $10,000 prize.
Commenting on the news, François R. Martelet, Chief Executive
Officer of NetScientific, said: "The SLAS Innovation Award is a
prestigious award with rigorous judging criteria. This is a
recognition for Vortex on the design of the VTX-1 Liquid Biopsy
System, with regards to its novel science and potential impact on
laboratory automation and screening.
"I am delighted to see Vortex's unique VTX-1 technology get the
profile it deserves, which we believe will help the company as it
moves into commercialisation phase. We wish Elodie the best of luck
with the award."
The full text of the announcement is below:
Vortex Biosciences Selected as Finalist for 2017 SLAS Innovation
Award
Elodie Sollier CSO of Vortex Biosciences is Presenting at SLAS
as 1 of 9 Finalists for the Innovation Award
MENLO PARK, CA, February 6 - Vortex Biosciences, provider of
circulating tumor cell (CTC) capture systems, today announced that
Chief Scientific Officer (CSO) Elodie Sollier has been selected as
1 of 9 finalists for the 2017 SLAS Innovation Award. Elodie is a
candidate for the award based on her presentation titled "Vortex
Technology for fast and label-free isolation of circulating tumor
cells from blood samples" which will be presented at SLAS on Monday
February 6(th) at 4:30 pm. As 1 of the 9 finalists, a panel of
judges will evaluate her presentation and compare it with the other
finalists to determine the winner of the 2017 award.
The annual SLAS Innovation Award recognizes extraordinary
achievement in innovative life sciences discovery and technology.
All those selected to deliver podium presentations at the annual
SLAS conference are eligible to be considered for this award. After
receiving nominations from 83 SLAS 2017 podium presenters, the SLAS
Innovation Award panel of judges invited 21 presenters to submit
extended abstracts for further consideration. Of these 21 extended
abstracts, 9 were identified as finalists. The complete judging
criteria can be seen on the Innovation Award page of the SLAS 2017
website.
"I am honored to be one of the finalists for something as
prestigious as the 2017 SLAS Innovation Award," said Elodie
Sollier, Chief Scientific Officer of Vortex Biosciences. "This is
further validation of the breakthrough technology the Vortex VTX-1
Liquid Biopsy System represents and the impact this will have on
cancer patients."
CTCs are relatively scarce, with concentrations as low as 1-10
CTCs/mL of whole blood, against a background of millions of white
blood cells and billions of red blood cells. Existing CTC isolation
technologies have been limited by complex sample processing, poor
scalability, low sample purity, reliance on cell surface proteins
for isolation, and dilute output volumes that require additional
cell concentration steps.
The fully automated, easy to use VTX-1 Liquid Biopsy System from
Vortex represents the next step in CTC isolation. Inside the VTX-1
chip, unlabeled CTCs in whole blood are selectively trapped in
microscale vortices while smaller red and white blood cells pass
through. Afterwards, CTCs can be collected into a variety of
containers for downstream analysis. With a cancer cell recovery of
65-75% and best in class CTC purity. The CTCs collected are
unbiased by their molecular characteristics. These cells are
intact, viable, and ready for downstream analysis. The VTX-1 offers
the best CTC samples available today.
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite,
CFO
Stifel Nicolaus Europe Tel +44 207 710 7624
Limited
Jonathan Senior
David Arch Tel: +44 (0)20 3709 5700
Ben Maddison netscientific@consilium-comms.com
Consilium Strategic
Communications
Mary-Jane Elliott /
Chris Gardner /
Jessica Hodgson / Chris
Welsh /
Laura Thornton
About NetScientific Plc
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases.
For more information, please visit the website at
www.netscientific.net
About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument harvests
intact circulating tumor cells from whole blood samples for use in
downstream research and clinical applications such as patient
stratification in clinical trials, monitoring disease progression
and drug treatment effectiveness. With a mission to enable
noninvasive diagnosis of cancer and real-time monitoring throughout
a patient's treatment, Vortex is at the forefront of accelerating
cancer research and improving patient outcomes. Vortex is a core
subsidiary of NetScientific plc, a transatlantic healthcare
technology group with an investment strategy focused on sourcing,
funding and commercializing technologies that significantly improve
the health and well-being of people with chronic diseases. For more
information, visit www.vortexbiosciences.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALFFLIFAITIID
(END) Dow Jones Newswires
February 09, 2017 02:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
